vendredi 14 septembre 2018

Onco Actu du 14 septembre 2018

1. Biologie

Cancer Cells Fuse with Immune Cells in Human Patients [The Scientist]

Putting Bone Metastasis in the Spotlight [NIH Director's Blog]

2. Etiologie

Scientists Map Interactions between Head and Neck Cancer and HPV Virus [Gladstone]

2.10 Etiologie - Alcool

Health researcher calls on NIH to retract statement about alcohol and cancer risk [STAT]

2.5 Etiologie - Gènes

Genetic testing could pick out people at three-fold increased risk of bone marrow cancer [Institute of Cancer Research]

3.1.1 Prévention - Tabac - e-cigs

Survey finds rapid increase in number of UK vapers [Reuters]

4.10 Dép., diag. & prono. - FDA, EMA, NICE,...

Blueprint for Breakthroughs - Charting the Course for Precision Medicine [FDA]

4.12 Biopsies liquides

Epic Sciences Raises $52M to Expand Cancer Diagnostic Portfolio [Xconomy]

4.2 Dép., diag. & prono. - Génome

Genetic testing helps predict disease recurrence in myelodysplastic syndrome [WUSTL]

5.10 Traitements - Essais

Half of European studies fail to report results: BMJ [FierceBiotech]

Pharma companies outperform institutions in European clinical trial reporting amid problematic overall trends — Oxford study [EndPoints]

5.12.10 Immunothérapies - Fusions et acquisitions

Boehringer Ingelheim Acquires All ViraTherapeutics Shares to Develop Next Generation Viral-Based Immuno-Oncology Therapies [Boehringer Ingelheim]

Boehringer Ingelheim joins the crowd and goes all-in on oncolytic viruses, buying ViraTherapeutics in $244M deal [EndPoints]

5.12.2 Immunothérapies - CAR-T, thérapies cellulaires

A Young Man's Experiment With A 'Living Drug' For Leukemia [NPR]

Engineered natural killer cells may be the next great cancer immunotherapy [Science]

5.12.3 Immunothérapies-combinaisons

Viruses show new promise in treating cancer [Institute of Cancer Research]

5.12.5 Immunothérapies - Pharma

Roche CEO Refuses to Cede Cancer's Hottest New Field to Merck [Bloomberg]

5.3 Traitements - FDA, EMA, NICE...

FDA provides update on its ongoing investigation into valsartan products; and reports on the finding of an additional impurity identified in one firm’s already recalled products [FDA]

Update on review of valsartan medicines [EMA]

5.3.4 Traitements - AMM (FDA, EMA,...)

US FDA approves Lumoxiti (moxetumomab pasudotox-tdfk) for certain patients with relapsed or refractory hairy cell leukaemia [AstraZeneca]

AstraZeneca grabs an FDA OK for its new leukemia drug, to be marketed as Lumoxiti [EndPoints]

FDA approves new kind of treatment for hairy cell leukemia [FDA]

FDA approves AstraZeneca's drug for rare form of blood cancer [Reuters]

5.5 ASCO

Multiple Financial Barriers Impede Patient Participation in Cancer Clinical Trials, According to New ASCO Policy Statement [ASCO]

6.1 Observation

Cancer waiting times 'at worst level ever' in England [BBC News]

6.12 Ethique

Top Official at Memorial Sloan Kettering Resigns After Failing to Disclose Industry Ties [ProPublica]

6.5 Médecines alternatives/complémentaires

Are crowdfunding sites promoting quack treatments for cancer? [NHS]

Crowdfunded cancer treatments - do they work? [BBC News]

6.6 Publications

European countries demand that publicly funded research should be free to all [The Economist]

6.9 Controverses

Prominent health policy researcher resigns from Dartmouth over plagiarism dispute [STAT]